# Steno Diabetes Center Copenhagen

**Type:** Funders  
**Canonical URL:** https://scholariq.org/funders/steno-diabetes-center-copenhagen/

## Facts

| Field | Value |
| --- | --- |
| Country | DK |
| OpenAlex ID | https://openalex.org/F4320318293 |
| Works | 2,334 |

## Funder papers

- [Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes](https://scholariq.org/papers/effects-of-semaglutide-on-chronic-kidney-disease-in-patients-with-type-2/)
- [Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial](https://scholariq.org/papers/finerenone-reduces-risk-of-incident-heart-failure-in-patients-with-chronic/)
- [Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials](https://scholariq.org/papers/effects-of-once-weekly-subcutaneous-semaglutide-on-kidney-function-and-safety-in/)
- [Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes](https://scholariq.org/papers/finerenone-in-heart-failure-and-chronic-kidney-disease-with-type-2-diabetes-fine/)
- [Effects of Semaglutide on Heart Failure Outcomes in Diabetes and Chronic Kidney Disease in the FLOW Trial](https://scholariq.org/papers/effects-of-semaglutide-on-heart-failure-outcomes-in-diabetes-and-chronic-kidney/)
- [Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure](https://scholariq.org/papers/effects-of-dapagliflozin-in-patients-with-kidney-disease-with-and-without-heart/)
- [A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease](https://scholariq.org/papers/a-comparative-post-hoc-analysis-of-finerenone-and-spironolactone-in-resistant/)
- [Correlates and Consequences of an Acute Change in eGFR in Response to the SGLT2 Inhibitor Dapagliflozin in Patients with CKD](https://scholariq.org/papers/correlates-and-consequences-of-an-acute-change-in-egfr-in-response-to-the-sglt2/)
- [Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial](https://scholariq.org/papers/effect-of-dapagliflozin-on-kidney-and-cardiovascular-outcomes-by-baseline-kdigo/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.